EP0409845A1 - Method for protection from chemotherapeutic side effects - Google Patents

Method for protection from chemotherapeutic side effects

Info

Publication number
EP0409845A1
EP0409845A1 EP89902904A EP89902904A EP0409845A1 EP 0409845 A1 EP0409845 A1 EP 0409845A1 EP 89902904 A EP89902904 A EP 89902904A EP 89902904 A EP89902904 A EP 89902904A EP 0409845 A1 EP0409845 A1 EP 0409845A1
Authority
EP
European Patent Office
Prior art keywords
derivative
aminopropylamino
ethyl dihydrogen
dihydrogen phosphorothioate
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP89902904A
Other languages
German (de)
French (fr)
Other versions
EP0409845A4 (en
Inventor
Philip S. Schein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP0409845A1 publication Critical patent/EP0409845A1/en
Publication of EP0409845A4 publication Critical patent/EP0409845A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Chemotherapy is one of the most useful treatments available to present day medicine in the struggle against cancer.
  • chemotherapeutic agents powerful alkylating agents, antibiotics and platinum-containing compounds have found wide use through the treatment of a variety of cancers.
  • doxorubicin and its derivatives can cause cardiac toxicity and bone marrow toxicity.
  • the mitomycin family and platinum-containing compounds such as carboplatin can cause bone marrow toxicity in a patient.
  • the amount and frequency of chemotherapeutic agent administration may be limited to levels which are below the optimum level for treatment of the cancer from which the patient suffers.
  • Doxorubicin (and derivatives such as the hydrochloride derivative, sold under the name ADRIAMYCIN) presently is administered in chemotherapy about once every 3 to 4 weeks in an amount of about 25 to 100 mg/m 2 patient surface area.
  • the dosage is commonly about 60 mg/m 2 .
  • the frequency and amount of the agent administered is limited because of the cardiotoxic and bone marrow toxic side effects associated with its administration.
  • mitomycin family which includes mitomycin A, mitomycin B, mitomycin C and N-methyl mitomycin C (porfiromycin).
  • Mitomycin C for example, is presently administered about once every 4 to 6 weeks in amounts of about 5 to 30 mg/m 2 , usually about 10 mg/m 2 .
  • the frequency and amount administered is limited due to the bone marrow toxicity associated with administration of the mitomycins.
  • Carboplatin a second generation analog of cisplatin (both from Bristol-Myers), is administered about once every 3 to 4 weeks in amounts of about 200-800 mg/m 2 , normally about 400 mg/m 2 .
  • the frequency and amount administered is limited due to the bone marrow toxicity associated with carboplatin administration.
  • This invention protects a patient against the undesired side effects of the chemotherapeutic agents without significant damage to the beneficial therapeutic properties of the chemotherapeutic agents through the administration of S -2 - ( 3 -aminopr opylamino) ethyl dihydrogen phosphorothioate (and pharmaceutically acceptable derivatives thereof) in an amount sufficient to protect the patient against the cardiac toxicity and/or bone marrow toxicity discussed above.
  • S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate has the structural formula:
  • S-2-(3- aminopropylamino) ethyl dihydrogen phosphorothioate but also to pharmaceutically acceptable derivatives such as alkali metal salts and hydrates thereof.
  • S-2-(3- aminopropylamino) ethyl dihydrogen phosphorothioate and its derivatives may be prepared in accordance with the methods disclosed in U.S. Patent No. 3,892,824 to Piper et al., the disclosure of which is incorporated herein by reference.
  • S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or a pharmaceutically useful derivatives thereof The amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate can be from about 300 to 1,000 mg/m 2 , with a dosage of about 740 mg/m 2 being preferred.
  • the S -2 -(3-aminopropylamino) ethyl dihydrogen phosphorothioate or its derivative should be administered either with, or more preferably, before administration of the chemotherapeutic agent. Particularly preferred is drip intravenous infusion in a buffered aqueous solution 15 to 30 minutes before administration of the chemotherapeutic agent. Oral administration is also desirable.
  • the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate can be stored frozen at low temperatures, e.g., -70°C.
  • the I.V. carrier solution may be a buffered solution of 5% dextrose in Ringers lactate, having a pH of about 7.2 to 7.4. This solution can be made by adding 20 cc of 44.9 mEq sodium bicarbonate to 1 liter of 5% dextrose in Ringers lactate.
  • 9.3 cc of the solution can be added to a vial containing 500 mg of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate to produce a solution containing 50 mg/cc of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate.
  • further buffered solution can be added for a total volume of 50 cc, and the resulting solution can be administered to a patient over a period of about 15 minutes, using a volumetric pump.
  • S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate binds to normal cells in competition with the chemotherapeutic agent, but not to tumors.
  • S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate may be taken up by normal cells, but not tumor cells. It thereby protects the normal tissues by then binding with and inactivating the chemotherapeutic agents.
  • S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate is not taken up by cancerous tissues, it leaves them open to attack by the chemotherapeutic agents. Significant improvement is expected in white blood cell and granulocyte nadirs, as well as duration of nadirs (or time to recovery). This will allow for the safer administration of conventional dosages of carboplatin and mitomycins and for the safer administration of higher clinical dosages. A significant reduction in the damage to cardiac muscle by doxorubicin will also allow for safer administration of higher cumulative clinical doses.
  • a solution of 2-(3-aminopropylamino)ethanol (25.0 g. 0.212 mole) in 48 percent hydrobromic acid (200 ml) is distilled until 35 ml of distillate has been collected.
  • the solution is refluxed and periodically, more distillate is collected.
  • the total volume of distillate removed in 7 distillation periods is 160 ml. or 80 percent of the original volume of 48 percent hydrobromic acid and the time of continuous boiling is approximately 48 hours.
  • the residual solution is then evaporated to dryness under reduced pressure with the aid of several added portions of methanol.
  • the crystalline residue is thoroughly triturated with acetone, collected, and washed on the funnel with acetone.
  • Trisodium phosphorothioate (6.93 g, 38.5 mmoles) is gradually added in small portions with vigorous stirring to water (38 ml) cooled externally by means of a water bath (15o-20°C.).
  • N-(2- bromoethyl)-1.3-propanediamine dihydrobromide (13.3 g, 38.8 mmoles).
  • N,N-dimethylformamide (19 ml) is added with continued external cooling at 15°-20oC.
  • the solution has been stirred at about 20oC for 90 minutes, it is poured into methanol (250 ml), and the mixture is refrigerated at 4oC overnight.
  • the white precipitate that formed is collected and pressed as dry as possible on the funnel.
  • the damp solid is dissolved in water (40 ml), and the solution is filtered.
  • Addition of methanol (250 ml) reprecipitates the product.
  • the product is collected and washed on the funnel, first with methanol and finally with ether.
  • the white solid is dried in vacuo at room temperature, then exposed to ambient conditions of the laboratory for 5 hours, and bottled under nitrogen and stored in a freezer.
  • the yield of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate monohydrate, mp 160°-161°C. dec. is 8.15 g (91%).

Abstract

Le S-2-(3-aminopropylamino)éthyl dihydrogéno-phosphorothiotate et des dérivés pharmaceutiquement acceptables de ce composé sont utilisés pour protéger un patient soumis à un traitement chimiothérapique contre les effets secondaires toxiques pour le coeur et pour la moelle osseuse, associés à l'administration d'agents chimiothérapiques.S-2- (3-aminopropylamino) ethyl dihydrogenophosphorothiotate and pharmaceutically acceptable derivatives of this compound are used to protect a patient undergoing chemotherapy against toxic side effects for the heart and bone marrow, associated with administration of chemotherapeutic agents.

Description

METHOD FOR PROTECTION FROM CHEMOTHERAPEDTIC SIDE EFFECTS Chemotherapy is one of the most useful treatments available to present day medicine in the struggle against cancer. Among known chemotherapeutic agents, powerful alkylating agents, antibiotics and platinum-containing compounds have found wide use through the treatment of a variety of cancers.
However, the anti-cancer effectiveness of these chemotherapeutic agents is limited by the effect the agent can have on non-cancerous portions of a patient's system. For example, doxorubicin and its derivatives can cause cardiac toxicity and bone marrow toxicity. The mitomycin family and platinum-containing compounds such as carboplatin can cause bone marrow toxicity in a patient. As a result of these side effects, the amount and frequency of chemotherapeutic agent administration may be limited to levels which are below the optimum level for treatment of the cancer from which the patient suffers.
Doxorubicin (and derivatives such as the hydrochloride derivative, sold under the name ADRIAMYCIN) presently is administered in chemotherapy about once every 3 to 4 weeks in an amount of about 25 to 100 mg/m2 patient surface area. The dosage is commonly about 60 mg/m2. The frequency and amount of the agent administered is limited because of the cardiotoxic and bone marrow toxic side effects associated with its administration.
Another group of anti-tumor antibiotics is the mitomycin family, which includes mitomycin A, mitomycin B, mitomycin C and N-methyl mitomycin C (porfiromycin). Mitomycin C, for example, is presently administered about once every 4 to 6 weeks in amounts of about 5 to 30 mg/m2, usually about 10 mg/m2. The frequency and amount administered is limited due to the bone marrow toxicity associated with administration of the mitomycins. Carboplatin, a second generation analog of cisplatin (both from Bristol-Myers), is administered about once every 3 to 4 weeks in amounts of about 200-800 mg/m2, normally about 400 mg/m2. The frequency and amount administered is limited due to the bone marrow toxicity associated with carboplatin administration.
This invention protects a patient against the undesired side effects of the chemotherapeutic agents without significant damage to the beneficial therapeutic properties of the chemotherapeutic agents through the administration of S -2 - ( 3 -aminopr opylamino) ethyl dihydrogen phosphorothioate (and pharmaceutically acceptable derivatives thereof) in an amount sufficient to protect the patient against the cardiac toxicity and/or bone marrow toxicity discussed above.
S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate has the structural formula:
NH2(CH2) 3NH(CH2) 2SPO3H2 The present application is directed not only to S-2-(3- aminopropylamino) ethyl dihydrogen phosphorothioate, but also to pharmaceutically acceptable derivatives such as alkali metal salts and hydrates thereof. S-2-(3- aminopropylamino) ethyl dihydrogen phosphorothioate and its derivatives may be prepared in accordance with the methods disclosed in U.S. Patent No. 3,892,824 to Piper et al., the disclosure of which is incorporated herein by reference.
The dangers of cardiac toxicity and bone marrow toxicity discussed above are significantly reduced by the administration of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or a pharmaceutically useful derivatives thereof. The amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate can be from about 300 to 1,000 mg/m2, with a dosage of about 740 mg/m2 being preferred. The S -2 -(3-aminopropylamino) ethyl dihydrogen phosphorothioate or its derivative should be administered either with, or more preferably, before administration of the chemotherapeutic agent. Particularly preferred is drip intravenous infusion in a buffered aqueous solution 15 to 30 minutes before administration of the chemotherapeutic agent. Oral administration is also desirable.
By way of example, the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate can be stored frozen at low temperatures, e.g., -70°C. The I.V. carrier solution may be a buffered solution of 5% dextrose in Ringers lactate, having a pH of about 7.2 to 7.4. This solution can be made by adding 20 cc of 44.9 mEq sodium bicarbonate to 1 liter of 5% dextrose in Ringers lactate. 9.3 cc of the solution can be added to a vial containing 500 mg of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate to produce a solution containing 50 mg/cc of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate. Prior to administration, further buffered solution can be added for a total volume of 50 cc, and the resulting solution can be administered to a patient over a period of about 15 minutes, using a volumetric pump.
While not wishing to be bound to one particular theory of protection, it is believed that S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate binds to normal cells in competition with the chemotherapeutic agent, but not to tumors. Thus, S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate may be taken up by normal cells, but not tumor cells. It thereby protects the normal tissues by then binding with and inactivating the chemotherapeutic agents. Since S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate is not taken up by cancerous tissues, it leaves them open to attack by the chemotherapeutic agents. Significant improvement is expected in white blood cell and granulocyte nadirs, as well as duration of nadirs (or time to recovery). This will allow for the safer administration of conventional dosages of carboplatin and mitomycins and for the safer administration of higher clinical dosages. A significant reduction in the damage to cardiac muscle by doxorubicin will also allow for safer administration of higher cumulative clinical doses.
EXAMPLES S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate monohydrate H2N(CH2) 3NHCH2CH2SPP3H2.H2P
A solution of 2-(3-aminopropylamino)ethanol (25.0 g. 0.212 mole) in 48 percent hydrobromic acid (200 ml) is distilled until 35 ml of distillate has been collected. The solution is refluxed and periodically, more distillate is collected. The total volume of distillate removed in 7 distillation periods is 160 ml. or 80 percent of the original volume of 48 percent hydrobromic acid and the time of continuous boiling is approximately 48 hours. The residual solution is then evaporated to dryness under reduced pressure with the aid of several added portions of methanol. The crystalline residue is thoroughly triturated with acetone, collected, and washed on the funnel with acetone. After the produce has been pressed as dry as possible on the funnel, it is dissolved in a slight excess of boiling methanol and the solution is filtered. Addition of acetone to the filtrate precipitates pure N-(2-bromoethyl)-1,3-propanediamine dihydrobromide as colorless crystals, which are dried in vacuo over phosphorus pentoxide; yield 58.0 g (80%), mp 205º-206°C.
Trisodium phosphorothioate (6.93 g, 38.5 mmoles) is gradually added in small portions with vigorous stirring to water (38 ml) cooled externally by means of a water bath (15º-20°C.). To the resulting suspension is added N-(2- bromoethyl)-1.3-propanediamine dihydrobromide (13.3 g, 38.8 mmoles). After a few minutes, complete solution occurs and N,N-dimethylformamide (19 ml) is added with continued external cooling at 15°-20ºC. After the solution has been stirred at about 20ºC for 90 minutes, it is poured into methanol (250 ml), and the mixture is refrigerated at 4ºC overnight. The white precipitate that formed is collected and pressed as dry as possible on the funnel. The damp solid is dissolved in water (40 ml), and the solution is filtered. Addition of methanol (250 ml) reprecipitates the product. After the mixture has been refrigerated about 1 hour, the product is collected and washed on the funnel, first with methanol and finally with ether. The white solid is dried in vacuo at room temperature, then exposed to ambient conditions of the laboratory for 5 hours, and bottled under nitrogen and stored in a freezer. The yield of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate monohydrate, mp 160°-161°C. dec. is 8.15 g (91%). Anal. Calcd for C5H15N2O3PS.H2O: C-25.86; H-7.38; N-12.07. Found: C.25.83; H-7.27; N-11.81.
While a detailed description of the present invention has been provided above, the present invention is not limited thereto, but rather is defined by the following claims.

Claims

WHAT IS CLAIMED IS:
1. A method for protecting a patient undergoing chemotherapy involving administration of doxorubicin or a pharmaceutically acceptable derivative thereof from undesired cardiotoxic side effects resulting from the administration of the doxorubicin or derivative thereof, the method for protecting comprising administering to the patient an amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or a pharmaceutically acceptable derivative thereof sufficient to protect the patient against the cardiotoxic side effects.
2. The method of claim 1, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered intravenously.
3. The method of claim 2, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered about 15 to 30 minutes before administration of the doxorubicin or derivative thereof.
4. The method of claim 2, wherein the amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is about 300 to 1,000 mg/m2 of patient surface area.
5. The method of claim 4, wherein the amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is about 740 mg/m2.
6. The method of claim 2, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered via drip intravenous infusion in a buffered aqueous solution.
7. A method for protecting a patient undergoing chemotherapy involving administration of doxorubicin or a pharmaceutically acceptable derivative thereof from undesired bone marrow toxic side effects resulting from the administration of the doxorubicin or derivative thereof, the method for protecting comprising administering to the patient an amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or a pharmaceutically acceptable derivative thereof sufficient to protect the patient against the bone marrow toxic side effects.
8. The method of claim 7, wherein the S-2-(3-aminoproplamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered intravenously.
9. The method of claim 8, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered about 15 to 30 minutes before administration of the doxorubicin or derivative thereof.
10. The method of claim 8, wherein the amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is about 300 to 1,000 mg/m2 of patient surface area.
11. The method of claim 10, wherein the amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is about 740 mg/m2.
12. The method of claim 8, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered via drip intravenous infusion in a buffered aqueous solution.
13. A method for protecting a patient undergoing chemotherapy involving administration of a mitomycin or a pharmaceutically acceptable derivative thereof from undesired bone marrow toxic side effects resulting from the administration of the mitomycin or derivative thereof, the method for protecting comprising administering to the patient an amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or a pharmaceutically acceptable derivative thereof sufficient to protect the patient against the bone marrow toxic side effects.
14. The method of claim 13, wherein the mitomycin is mitomycin A.
15. The method of claim 13, wherein the mitomycin is mitomycin B.
16. The method of claim 13, wherein the mitomycin is mitomycin C.
17. The method of claim 13, wherein the mitomycin is N-methyl mitomycin C.
18. The method of claim 13, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered intravenously.
19. The method of claim 18, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered about 15 to 30 minutes before administration of the mitomycin or derivative thereof.
20. The method of claim 18, wherein the amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is about 300 to 1,000 mg/m2 of patient surface area.
21. The method of claim 20, wherein the amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is about 740 mg/m2.
22. The method of claim 18, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered via drip intravenous infusion in a buffered aqueous solution.
23. A method for protecting a patient undergoing chemotherapy involving administration of carboplatin or a pharmaceutically acceptable derivative thereof from undesired bone marrow toxic side effects resulting from the administration of the carboplatin or derivative thereof, the method for protecting comprising administering to the patient an amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or a pharmaceutically acceptable derivative thereof sufficient to protect the patient against the bone marrow toxic side effects.
24. The method of claim 23, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered intravenously.
25. The method of claim 24, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered about 15 to 30 minutes before administration of the carboplatin or derivative thereof.
26. The method of claim 24, wherein the amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is about 300 to 1,000 mg/m2 of patient surface area.
27. The method of claim 26, wherein the amount of S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is about 740 mg/m2.
28. The method of claim 24, wherein the S-2-(3-aminopropylamino) ethyl dihydrogen phosphorothioate or derivative thereof is administered via drip intravenous infusion in a buffered aqueous solution.
EP19890902904 1988-02-23 1989-02-21 Method for protection from chemotherapeutic side effects Withdrawn EP0409845A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15910488A 1988-02-23 1988-02-23
US159104 1988-02-23

Publications (2)

Publication Number Publication Date
EP0409845A1 true EP0409845A1 (en) 1991-01-30
EP0409845A4 EP0409845A4 (en) 1991-07-03

Family

ID=22571099

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890902904 Withdrawn EP0409845A4 (en) 1988-02-23 1989-02-21 Method for protection from chemotherapeutic side effects

Country Status (5)

Country Link
EP (1) EP0409845A4 (en)
JP (1) JPH03503888A (en)
AU (1) AU636107B2 (en)
CA (1) CA1336506C (en)
WO (1) WO1989007942A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827974A1 (en) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh COMBINATION PREPARATIONS OF PROTEINKINASE-C INHIBITORS WITH LIPIDS, LIPID ANALOGS, CYTOSTATICA OR INHIBITORS OF PHOSPHOLIPASES
US5567686A (en) * 1992-03-13 1996-10-22 Arch Development Corporation Method for protection against genotoxic mutagenesis
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US6239119B1 (en) 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6489312B1 (en) 1999-06-15 2002-12-03 Medimmune Oncology, Inc. Pharmaceutical formulations comprising aminoalkyl phosphorothioates
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
CN102260288B (en) * 2010-06-08 2014-02-26 成都大有得药业有限公司 Synthesis method of 3-amino-propyl aminoethyl thiophosphate trihydrate
RU2450791C1 (en) * 2010-10-18 2012-05-20 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Method for determining cardiotoxic complications in patients with chronic lymphatic leukemia
CN104230984B (en) * 2013-06-08 2017-02-08 国药集团国瑞药业有限公司 Preparation method for trihydrate 3-amino propyl aminoethyl thiophosphoric acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656034A (en) * 1985-05-20 1987-04-07 Survival Technology, Inc. Absorption enhancing agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
American Association for Cancer Research Proceedings, Vol. 22, March 1981, page 271, Abstract No. 1075, Washington, DC, US; T.L. PHILLIPS et al.: "Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs, intestinal crypt cells, EMT6 tumor", whole article. *
Drugs of the Future, Vol. 14, No. 11, November 1989, pages 1105-1107; whole article. *
J. Pharmacobio.-Dynamics, Vol. 3, No. 7, July 1980, page s-21; M. ONODA et al.: "Effect of various kinds of drugs in vitro on the proliferation of leukopoietic stem cells (CFU-C)", whole article. *
Proceedings of the 9th Annual Conference of the IEEE Engineering in Medicine and Biology Society, Boston, 13th-16th November 1987, pages 1443-1445, New York, US; M.-A. RIX-MONTEL: "Radioprotective effects of thiophosphates", whole article. *
See also references of WO8907942A1 *

Also Published As

Publication number Publication date
WO1989007942A1 (en) 1989-09-08
AU636107B2 (en) 1993-04-22
EP0409845A4 (en) 1991-07-03
JPH03503888A (en) 1991-08-29
AU3194089A (en) 1989-09-22
CA1336506C (en) 1995-08-01

Similar Documents

Publication Publication Date Title
US4296105A (en) Derivatives of doxorubicine, their preparation and use
KR0142907B1 (en) Bone marrow suppressing agents
US6537990B1 (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
US4357324A (en) Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
IL93556A (en) Pharmaceutical compositions comprising stabilized nitric oxide-primary amine complexes useful as cardiovascular agents
GB1583661A (en) Tumour antidote
CA1336506C (en) Method for protection from chemotherapeutic side effects
JP2714402B2 (en) Cancer metastasis inhibitor
US4066650A (en) Keto-aldehyde-amine addition products and method of making same
EP0768084B1 (en) Cancerous metastasis inhibitor
CA2145229A1 (en) Suppressory compositions against hepatic metastases of tumors
NL8100579A (en) APPLICATION OF NOOETROOP EFFECTIVE COMPOUNDS.
RU2097040C1 (en) Use of creatine phosphate for treatment of tumors and pharmaceutical preparations showing antitumor activity
AU2003298077A1 (en) Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours
FI78069B (en) FOERFARANDE FOER FRAMSTAELLNING AV SAOSOM LAEKEMEDEL ANVAENDBARA ACYLERADE ENAMIDFOERENINGAR.
US20080293648A1 (en) Compositions and Methods for Cancer Treatment
RU2353623C1 (en) Corrector of cytostatic polychemotherapy
JP2000302762A (en) Glycidiazole metal salt of sensitive enhancer in radiotherapy and chemotherapy and its production and use
EP0432630B1 (en) Antitumor agent
US7732485B2 (en) Treatment of cancer
US3169091A (en) Process for inhibiting tumors with substituted pyrazoles
JPS62919B2 (en)
US4423076A (en) 1-Branched-alkyl-3-(2-haloethyl)-3-nitrosoureas as novel antitumor agents
JPS63264580A (en) 3-(2-haloalkyl)-1,4-oxathiin and 2-(2- haloalkyl)-1,4-dithiin
NL8901623A (en) MITOMYCIN PHOSPHATE DERIVATIVES.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19910516

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920305

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930513